People with CRD deserve a better deal. This ERS Monograph brings together the state-of-the-art in palliative care in this field, with the aim of helping clinicians and researchers provide that better deal and redress the balance after many years of serious neglect. Disclosures: D.C. Currow is an unpaid advisory board member for Helsinn Pharmaceuticals. He is also a paid consultant and received payment for intellectual property with Mayne Pharma, and is a consultant with Specialised Therapeutics Australia Pty Ltd. M.J. Johnson has worked as a clinical consultant to Mayne Pharma and received institutional payment. xii
Previous Page Next Page